Hello guys, Welcome to Africa's Largest Video Search Engine, and you are watching Bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity. and this video is uploaded by VJOncology at 2022-06-08T06:15:05-07:00. We are just promoting this video only for entertainment and educational purpose only. I hop you like our Video Search Engine. [U2uSNTZRUQ8]
| Name | Bevacizumab for the treatment of patients with ovarian cancer exhibiting poor chemosensitivity |
| Video Uploader | Video From VJOncology |
| Upload Date | This Video Uploaded At 08-06-2022 13:15:05 |
| Video Discription | Benoit You, MD, PhD, Centre Hospitalier Lyon-Sud, Saint-Genis-Laval, France, discusses bevacizumab in the treatment landscape of patients with ovarian cancer. As indicated by the data from the Phase III GOG-0218 (NCT00262847) trial which evaluated carboplatin and paclitaxel with or without bevacizumab in patient with stage III or stage IV ovarian, epithelial, primary peritoneal, or fallopian tube cancer, bevacizumab should be prioritized in patients with poor chemosensitivity. According to the results of GOG-0218, which showed a benefit of bevacizumab in patients who were poorly chemosensitive, this can increase the efficacy of chemotherapy and improve the overall-survival of this patient population. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL. [U2uSNTZRUQ8] |
| Category | Education |
| Tags | Speaker: Benoit You | Institution: Centre Hospitalier Lyon-Sud | Event: ASCO 2022 | Format: Interview | Subject: Ovarian Cancer | Field: Trial Updates | Field: Treatment | Medicines: Antibodies | Field: Immuno-Oncology | Medicines: Bevacizumab | Medicines: Carboplatin | Medicines: Paclitaxel | NCT00262847 | Subject: Gynecological Cancer | Trial: GOG-0218 | Field: Policy |
